Fermenta Biotech Lists on India’s National Stock Exchange

▴
Fermenta Biotech Limited, one of the world's largest manufacturers of Vitamin D3 API, and a growing portfolio of premium-grade nutritional ingredients, green chemistry, APIs and customized food premixes, today announced the successful listing of its equity shares on the National Stock Exchange of India Limited (NSE).

Mumbai, 4 August 2026: Fermenta Biotech Limited, one of the world's largest  manufacturers of Vitamin D3 API, and a growing portfolio of premium-grade nutritional  ingredients, green chemistry, APIs and customized food premixes, today announced  the successful listing of its equity shares on the National Stock Exchange of India  Limited (NSE).  

Effective 4 August 2026, the Company’s 2,94,30,987 equity shares, of face value ₹5  each, have been listed and admitted to dealings on the NSE under the symbol  FERMENTA and ISIN INE225B01021. The Company’s equity shares will continue to  remain listed on the BSE under Scrip Code 506414. 

The milestone was commemorated through a ceremonial bell-ringing event held at the NSE’s Exchange Plaza office in Mumbai’s Bandra Kurla Complex. Present were  representatives from NSE, Fermenta’s Board and senior leadership team, and other  stakeholders. 

The listing marks a milestone in Fermenta’s 75-year journey. Founded in 1951 and listed  on the BSE since 1977, the Company has grown from its pharmaceutical and  biotechnology foundations into a globally recognised manufacturer serving customers  in more than 60 countries, anchored by decades of technical expertise and backed by  rigorous global compliance standards and certifications. 

Listed on the BSE since 1977, Fermenta’s NSE listing reflects the Company’s growth,  expanding global customer base and widening investor interest. It provides access to  shareholders and market participants across both major Indian stock exchanges,  supporting broader participation, improved visibility and more efficient price discovery.   

Comment from Prashant Nagre, Managing Director  

“Fermenta’s listing on the NSE represents a significant milestone in a landmark year for  the Company, as we commemorate 75 years of Fermenta and nearly five decades as a  publicly listed enterprise, alongside important recognitions in food safety and  workplace culture. It reflects a journey shaped by resilience and a path forward defined 

by innovation, scale and focus. We will continue to enhance our capabilities across  nutrition, food fortification, green chemistry and specialised solutions. 

The NSE listing further strengthens our capital-market presence and reaffirms our  commitment to transparency, responsible governance and consistent engagement  with shareholders. We extend our sincere appreciation to our promoters, Board,  shareholders, employees, customers, partners and all other stakeholders for their  continued confidence in Fermenta.” 

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026